KURA Kura Oncology Inc

Price (delayed)

$18.33

Market cap

$1.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.73

Enterprise value

$1.12B

Highlights
The quick ratio has soared by 61% YoY
The equity has soared by 188% YoY but it has contracted by 4.1% from the previous quarter
The debt has surged by 56% year-on-year but it has declined by 9% since the previous quarter
Kura Oncology's net income has decreased by 48% YoY and by 13% from the previous quarter
The company's EPS fell by 11% YoY and by 2.4% QoQ

Key stats

What are the main financial stats of KURA
Market
Shares outstanding
66.27M
Market cap
$1.21B
Enterprise value
$1.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$100.57M
EBITDA
-$100.27M
Free cash flow
-$80.22M
Per share
EPS
-$1.73
Free cash flow per share
-$1.21
Book value per share
$8.85
Revenue per share
$0
TBVPS
$9.37
Balance sheet
Total assets
$620.26M
Total liabilities
$34.28M
Debt
$11.7M
Equity
$585.99M
Working capital
$585.57M
Liquidity
Debt to equity
0.02
Current ratio
24.29
Quick ratio
24.03
Net debt/EBITDA
0.99
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-20.6%
Return on equity
-22.2%
Return on invested capital
-31.6%
Return on capital employed
-16.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KURA stock price

How has the Kura Oncology stock price performed over time
Intraday
4.15%
1 week
-3.58%
1 month
-13.29%
1 year
3.91%
YTD
-43.88%
QTD
-12.09%

Financial performance

How have Kura Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$102.6M
Net income
-$101.11M
Gross margin
N/A
Net margin
N/A
Kura Oncology's net income has decreased by 48% YoY and by 13% from the previous quarter
The company's operating income fell by 41% YoY and by 12% QoQ

Growth

What is Kura Oncology's growth rate over time

Valuation

What is Kura Oncology stock price valuation
P/E
N/A
P/B
2.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 11% YoY and by 2.4% QoQ
The equity has soared by 188% YoY but it has contracted by 4.1% from the previous quarter
The stock's P/B is 45% below its 5-year quarterly average of 3.6 and 43% below its last 4 quarters average of 3.5

Efficiency

How efficient is Kura Oncology business performance
The return on equity has grown by 27% year-on-year and by 10% since the previous quarter
The ROA has grown by 26% YoY and by 10% from the previous quarter
The return on invested capital has increased by 15% year-on-year and by 15% since the previous quarter

Dividends

What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KURA.

Financial health

How did Kura Oncology financials performed over time
KURA's total assets has surged by 174% year-on-year but it is down by 4.2% since the previous quarter
The quick ratio has soared by 61% YoY
The debt is 98% smaller than the equity
The equity has soared by 188% YoY but it has contracted by 4.1% from the previous quarter
The debt has surged by 56% year-on-year but it has declined by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.